Novo Nordisk A/S (NVO) 55.33 $NVO
Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia World Congress in Orlando
PR Newswire - Mon Jul 11, 11:00AM CDT
Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia (WFH) World Congress in Orlando, FL, from July 24-28. The WFH Congress is the largest international meeting for the global bleeding disorders community.
NVO: 55.33 (-0.22)
Unique New Book Series from Novo Nordisk and JDRF Uses Customized Information by Age to Educate Children and Young Adults with Type 1 Diabetes
PR Newswire - Wed Jul 06, 8:00AM CDT
Novo Nordisk, the global diabetes leader and JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, announced today the launch of the first book series of its kind designed to guide children and their caregivers through the different ages and stages of life with T1D. The six-part book series, titled, "My Life, My Diabetes, My Way," includes booklets for small children (ages 2-6), tweens (ages 7-11), teens (ages 12-16), and young adults (ages 17-24), as well as a book for caregivers and a general diabetes informational book. Each booklet contains age-appropriate educational information and activities. The series is available to download for free at t1support.cornerstones4care.com and hard copies will be made available in pediatric and adult endocrinologist offices throughout the Unites States beginning July 5.
NVO: 55.33 (-0.22)
Eli Lilly Stock Up on FDA Advisory Panel Vote for Jardiance
Arpita Dutt - Zacks Investment Research - Thu Jun 30, 8:50AM CDT
Lilly (LLY) and its partner, Boehringer, are seeking FDA approval for the inclusion of data from the EMPA-REG OUTCOME study, which showed cardiovascular risk reduction.
JNJ: 123.00 (+0.08), NVO: 55.33 (-0.22), MRK: 59.55 (-0.05), LLY: 79.36 (-0.31)
Downgrade Alert for Novo Nordisk (NVO)
Comtex SmarTrend(R) - Wed Jun 29, 3:31AM CDT
Novo Nordisk (NYSE:NVO) was downgraded from Conviction Buy to Buy at Goldman Sachs today. The stock closed yesterday at $52.23 on volume of 933,000 shares, below average daily volume of 1.0 million. Novo Nordisk (NYSE:NVO) has potential upside of 36.1% based on a current price of $52.23 and analysts' consensus price target of $71.10. The stock should run into initial resistance at its 200-day moving average (MA) of $55.18 and subsequent resistance at its 50-day MA of $55.23.
NVO: 55.33 (-0.22)
EMA Grants Marketing Authorisation of mylife(TM) YpsoPump® for Use with NovoRapid® PumpCart®, Marking the Start of a Collaboration Between Novo Nordisk and Ypsomed
PR Newswire Europe - Tue Jun 28, 12:01AM CDT
BAGSVARD, Denmark, June 28, 2016 /PRNewswire/ --
NVO: 55.33 (-0.22)
Brenntag Specialties Inc. (BSI) Expands Pharmaceutical, Over-the-Counter (OTC), and Personal Care Product Offering with Novo Nordisk Pharmatech A/S
PRWeb - Thu Jun 16, 9:09AM CDT
Brenntag Specialties, Inc. (BSI) and Novo Nordisk Pharmatech A/S have entered into a distribution agreement for Pharmaceutical Grade Quaternary Ammonium Compounds into the Pharmaceutical, Over-the-Counter (OTC), and Personal Care Markets in the United States & Puerto Rico.
NVO: 55.33 (-0.22)
Novo Nordisk (NVO) Reports Positive Trial Results on Victoza
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 2:17PM CDT
Novo Nordisk (NVO) announced results from the LEADER trial on Victoza at the American Diabetes Association's 76th Scientific Sessions.
ABT: 41.97 (-0.50), NVO: 55.33 (-0.22), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
Study Finds Victoza® Significantly Reduced the Risk of Heart Attack and Stroke in People with Type 2 Diabetes
CNW Group - Mon Jun 13, 7:52PM CDT
Diabetes community welcomes news that Victoza(® )reduces the risk of cardiovascular deaths by 22 per cent
NVO: 55.33 (-0.22)
Watch for Novo Nordisk to Potentially Rebound After Falling 1.01% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 4:23PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $54.20 to a high of $55.45. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $55.12 on volume of 608,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 55.33 (-0.22)
Faster-acting insulin aspart showed a statistically significant reduction in HbA(1c) in type 1 diabetes and a comparable HbA(1c) reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
CNW Group - Mon Jun 13, 11:40AM CDT
Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes
NVO: 55.33 (-0.22)
Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA
PR Newswire Europe - Mon Jun 06, 6:36AM CDT
BAGSVARD, Denmark, June 6, 2016 /PRNewswire/ --
NVO: 55.33 (-0.22)
Novo Nordisk (Prandin, NovoNorm, GlucoNorm, Prandimet); Daiichi Sankyo (Prandin) Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) - Research and Markets
BusinessWire - Fri Jun 03, 8:34AM CDT
Research and Markets has announced the addition of the "Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering.
NVO: 55.33 (-0.22)
Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:56AM CDT
Novo Nordisk (NVO) announced positive results on its pipeline candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), NVO: 55.33 (-0.22), SNY: 42.03 (-0.47)
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:20AM CDT
Sanofi's (SNY) fixed-ratio combination of Lantus and Lyxumia won FDA panel backing for the treatment of type II diabetes.
MDVN: 61.57 (-0.58), NVO: 55.33 (-0.22), BMY: 76.58 (+0.38), SNY: 42.03 (-0.47)
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
Zacks Equity Research - Zacks Investment Research - Wed May 25, 2:50PM CDT
Novo Nordisk (NVO) announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously (16-0) in favor of the approval of IDegLira for the treatment of adults with type II diabetes.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), NVO: 55.33 (-0.22), SNY: 42.03 (-0.47)
IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee
PR Newswire - Tue May 24, 6:39PM CDT
Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of Tresiba® (insulin degludec injection 100 Units/mL) and Victoza® (liraglutide) injection for the treatment of adults with type 2 diabetes.
NVO: 55.33 (-0.22)
IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee
Globe Newswire - Tue May 24, 4:24PM CDT
Bagsvaerd, Denmark, 24 May 2016 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba(R)) and liraglutide (Victoza(R)) for the treatment of adults with type 2 diabetes.
NVO: 55.33 (-0.22)
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
Arpita Dutt - Zacks Investment Research - Tue May 24, 7:07AM CDT
Sanofi's (SNY) diabetes combination drug will be coming up for review by an FDA advisory panel this week.
NVO: 55.33 (-0.22), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38), SNY: 42.03 (-0.47)
US and Europe Insulin Market 2016-2020 - Key Vendors are Sanofi, Novo Nordisk & Eli Lilly
GlobeNewswire - Tue May 24, 5:20AM CDT
Research and Markets has announced the addition of the "Insulin Market in the US and Europe 2016-2020" report to their offering.
NVO: 55.33 (-0.22), LLY: 79.36 (-0.31)
Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia World Congress in Orlando
PR Newswire - Mon Jul 11, 11:00AM CDT
Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia (WFH) World Congress in Orlando, FL, from July 24-28. The WFH Congress is the largest international meeting for the global bleeding disorders community.
NVO: 55.33 (-0.22)
Unique New Book Series from Novo Nordisk and JDRF Uses Customized Information by Age to Educate Children and Young Adults with Type 1 Diabetes
PR Newswire - Wed Jul 06, 8:00AM CDT
Novo Nordisk, the global diabetes leader and JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, announced today the launch of the first book series of its kind designed to guide children and their caregivers through the different ages and stages of life with T1D. The six-part book series, titled, "My Life, My Diabetes, My Way," includes booklets for small children (ages 2-6), tweens (ages 7-11), teens (ages 12-16), and young adults (ages 17-24), as well as a book for caregivers and a general diabetes informational book. Each booklet contains age-appropriate educational information and activities. The series is available to download for free at t1support.cornerstones4care.com and hard copies will be made available in pediatric and adult endocrinologist offices throughout the Unites States beginning July 5.
NVO: 55.33 (-0.22)
Eli Lilly Stock Up on FDA Advisory Panel Vote for Jardiance
Arpita Dutt - Zacks Investment Research - Thu Jun 30, 8:50AM CDT
Lilly (LLY) and its partner, Boehringer, are seeking FDA approval for the inclusion of data from the EMPA-REG OUTCOME study, which showed cardiovascular risk reduction.
JNJ: 123.00 (+0.08), NVO: 55.33 (-0.22), MRK: 59.55 (-0.05), LLY: 79.36 (-0.31)
Downgrade Alert for Novo Nordisk (NVO)
Comtex SmarTrend(R) - Wed Jun 29, 3:31AM CDT
Novo Nordisk (NYSE:NVO) was downgraded from Conviction Buy to Buy at Goldman Sachs today. The stock closed yesterday at $52.23 on volume of 933,000 shares, below average daily volume of 1.0 million. Novo Nordisk (NYSE:NVO) has potential upside of 36.1% based on a current price of $52.23 and analysts' consensus price target of $71.10. The stock should run into initial resistance at its 200-day moving average (MA) of $55.18 and subsequent resistance at its 50-day MA of $55.23.
NVO: 55.33 (-0.22)
EMA Grants Marketing Authorisation of mylife(TM) YpsoPump® for Use with NovoRapid® PumpCart®, Marking the Start of a Collaboration Between Novo Nordisk and Ypsomed
PR Newswire Europe - Tue Jun 28, 12:01AM CDT
BAGSVARD, Denmark, June 28, 2016 /PRNewswire/ --
NVO: 55.33 (-0.22)
Brenntag Specialties Inc. (BSI) Expands Pharmaceutical, Over-the-Counter (OTC), and Personal Care Product Offering with Novo Nordisk Pharmatech A/S
PRWeb - Thu Jun 16, 9:09AM CDT
Brenntag Specialties, Inc. (BSI) and Novo Nordisk Pharmatech A/S have entered into a distribution agreement for Pharmaceutical Grade Quaternary Ammonium Compounds into the Pharmaceutical, Over-the-Counter (OTC), and Personal Care Markets in the United States & Puerto Rico.
NVO: 55.33 (-0.22)
Novo Nordisk (NVO) Reports Positive Trial Results on Victoza
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 2:17PM CDT
Novo Nordisk (NVO) announced results from the LEADER trial on Victoza at the American Diabetes Association's 76th Scientific Sessions.
ABT: 41.97 (-0.50), NVO: 55.33 (-0.22), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38)
Study Finds Victoza® Significantly Reduced the Risk of Heart Attack and Stroke in People with Type 2 Diabetes
CNW Group - Mon Jun 13, 7:52PM CDT
Diabetes community welcomes news that Victoza(® )reduces the risk of cardiovascular deaths by 22 per cent
NVO: 55.33 (-0.22)
Watch for Novo Nordisk to Potentially Rebound After Falling 1.01% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 4:23PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $54.20 to a high of $55.45. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $55.12 on volume of 608,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 55.33 (-0.22)
Faster-acting insulin aspart showed a statistically significant reduction in HbA(1c) in type 1 diabetes and a comparable HbA(1c) reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
CNW Group - Mon Jun 13, 11:40AM CDT
Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes
NVO: 55.33 (-0.22)
Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA
PR Newswire Europe - Mon Jun 06, 6:36AM CDT
BAGSVARD, Denmark, June 6, 2016 /PRNewswire/ --
NVO: 55.33 (-0.22)
Novo Nordisk (Prandin, NovoNorm, GlucoNorm, Prandimet); Daiichi Sankyo (Prandin) Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) - Research and Markets
BusinessWire - Fri Jun 03, 8:34AM CDT
Research and Markets has announced the addition of the "Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)" report to their offering.
NVO: 55.33 (-0.22)
Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:56AM CDT
Novo Nordisk (NVO) announced positive results on its pipeline candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), NVO: 55.33 (-0.22), SNY: 42.03 (-0.47)
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:20AM CDT
Sanofi's (SNY) fixed-ratio combination of Lantus and Lyxumia won FDA panel backing for the treatment of type II diabetes.
MDVN: 61.57 (-0.58), NVO: 55.33 (-0.22), BMY: 76.58 (+0.38), SNY: 42.03 (-0.47)
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
Zacks Equity Research - Zacks Investment Research - Wed May 25, 2:50PM CDT
Novo Nordisk (NVO) announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously (16-0) in favor of the approval of IDegLira for the treatment of adults with type II diabetes.
ABT: 41.97 (-0.50), JNJ: 123.00 (+0.08), NVO: 55.33 (-0.22), SNY: 42.03 (-0.47)
IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee
PR Newswire - Tue May 24, 6:39PM CDT
Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of Tresiba® (insulin degludec injection 100 Units/mL) and Victoza® (liraglutide) injection for the treatment of adults with type 2 diabetes.
NVO: 55.33 (-0.22)
IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee
Globe Newswire - Tue May 24, 4:24PM CDT
Bagsvaerd, Denmark, 24 May 2016 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba(R)) and liraglutide (Victoza(R)) for the treatment of adults with type 2 diabetes.
NVO: 55.33 (-0.22)
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
Arpita Dutt - Zacks Investment Research - Tue May 24, 7:07AM CDT
Sanofi's (SNY) diabetes combination drug will be coming up for review by an FDA advisory panel this week.
NVO: 55.33 (-0.22), PFE: 36.31 (+0.07), BMY: 76.58 (+0.38), SNY: 42.03 (-0.47)
US and Europe Insulin Market 2016-2020 - Key Vendors are Sanofi, Novo Nordisk & Eli Lilly
GlobeNewswire - Tue May 24, 5:20AM CDT
Research and Markets has announced the addition of the "Insulin Market in the US and Europe 2016-2020" report to their offering.
NVO: 55.33 (-0.22), LLY: 79.36 (-0.31)
